US Drug Recall Register

FDA Drug Recalls

14,450 recalls · Class II, newest first

Risk Class IClass IIClass III
Status OngoingCompletedTerminated
Year 2026202520242023
Class II · Moderate risk Terminated

Cefazolin for injection USP

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 0264-3103-11 D-1117-2022
Class II · Moderate risk Terminated

Diprivan

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 63323-269-29 D-1116-2022
Class II · Moderate risk Terminated

Diprivan

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 63323-269-10 D-1115-2022
Class II · Moderate risk Terminated

Ofloxacin Otic Solution 0.3%

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 69238-1615-3 D-1114-2022
Class II · Moderate risk Terminated

Geodon for injection

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 0049-3920-83 D-1112-2022
Class II · Moderate risk Terminated

Sumatriptan Succinate Tablets

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 62756-522-69 D-1111-2022
Class II · Moderate risk Terminated

Metoprolol tablets 50 mg

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 57664-0477-52 D-1110-2022
Class II · Moderate risk Terminated

Pilocarpine HCL Ophthalmic Solution

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office D-1109-2022
Class II · Moderate risk Terminated

Tropicamide Ophthalmic Solution

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office D-1108-2022
Class II · Moderate risk Terminated

Triamcinolone Acetonide cream

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 0168-0004-15 D-1106-2022
Class II · Moderate risk Terminated

Prednisolone Acetate Ophthalmic Suspension

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 61314-637-05 D-1105-2022
Class II · Moderate risk Terminated

Pantoprazole Sodium for Injection

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 0781-3232-95 D-1104-2022
Class II · Moderate risk Terminated

Ondansetron HCL

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 65862-188-30 D-1103-2022
Class II · Moderate risk Terminated

Diphenhydramine HCl oral solution

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 0121-0978-10 D-1101-2022
Class II · Moderate risk Terminated

Verapamil HCL

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 04094-011-01 D-1100-2022
Class II · Moderate risk Terminated

Thrombin JMI

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 60793-215-05 D-1099-2022
Class II · Moderate risk Terminated

Epinephrine

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 04094-933-01 D-1098-2022
Class II · Moderate risk Terminated

Depo-Medrol

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 0009-3475-01 D-1097-2022
Class II · Moderate risk Terminated

Depo-Medrol

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 0009-3073-03 D-1096-2022
Class II · Moderate risk Terminated

Bupivacaine Hydrochloride

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 0409-1163-01 D-1095-2022
Class II · Moderate risk Terminated

Labetalol Hydrochloride Tablets

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 49884-122-01 D-1094-2022
Class II · Moderate risk Terminated

Prazosin Hydrochloride Capsules

Reason cGMP deviations: Temperature abuse

Mckesson Medical-Surgical Inc. Corporate Office NDC 0378-1101-01 D-1093-2022